Dr. Agarwal's Eye Hospital Limited

BSE:526783 Stock Report

Market Cap: ₹23.0b

Dr. Agarwal's Eye Hospital Valuation

Is 526783 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 526783 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 526783 (₹4768.8) is trading above our estimate of future cash flow value (₹1237.81)

Significantly Below Future Cash Flow Value: 526783 is trading above our estimate of future cash flow value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 526783?

Key metric: As 526783 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 526783. This is calculated by dividing 526783's market cap by their current earnings.
What is 526783's PE Ratio?
PE Ratio33x
Earnings₹698.50m
Market Cap₹23.05b

Price to Earnings Ratio vs Peers

How does 526783's PE Ratio compare to its peers?

The above table shows the PE ratio for 526783 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49.2x
KRSNAA Krsnaa Diagnostics
25.1x29.70%₹20.2b
SURAKSHA Suraksha Diagnostic
44.2x16.79%₹14.7b
539871 Thyrocare Technologies
45.1x22.70%₹62.0b
NEPHROPLUS Nephrocare Health Services
82.4x40.56%₹58.8b
526783 Dr. Agarwal's Eye Hospital
33xn/a₹23.0b

Price-To-Earnings vs Peers: 526783 is good value based on its Price-To-Earnings Ratio (33x) compared to the peer average (49.2x).


Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data


Price to Earnings Ratio vs Industry

How does 526783's PE Ratio compare vs other companies in the IN Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
543500 Evoq Remedies
4.9xn/aUS$938.70k
No more companies available in this PE range
526783 33.0xIndustry Avg. 36.7xNo. of Companies11PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 526783 is good value based on its Price-To-Earnings Ratio (33x) compared to the Indian Healthcare industry average (36.7x).


Price to Earnings Ratio vs Fair Ratio

What is 526783's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

526783 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 526783's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/18 13:16
End of Day Share Price 2026/04/17 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dr. Agarwal's Eye Hospital Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kameswari V. S. ChavaliFirstCall Research
Tushar ManudhaneMotilal Oswal Securities Ltd.